Postpartum depression: psychoneuroimmunological underpinnings and treatment

George Anderson, Michael Maes, George Anderson, Michael Maes

Abstract

Postpartum depression (PPD) is common, occurring in 10%-15% of women. Due to concerns about teratogenicity of medications in the suckling infant, the treatment of PPD has often been restricted to psychotherapy. We review here the biological underpinnings to PPD, suggesting a powerful role for the tryptophan catabolites, indoleamine 2,3-dixoygenase, serotonin, and autoimmunity in mediating the consequences of immuno-inflammation and oxidative and nitrosative stress. It is suggested that the increased inflammatory potential, the decreases in endogenous anti-inflammatory compounds together with decreased omega-3 poly-unsaturated fatty acids, in the postnatal period cause an inflammatory environment. The latter may result in the utilization of peripheral inflammatory products, especially kynurenine, in driving the central processes producing postnatal depression. The pharmacological treatment of PPD is placed in this context, and recommendations for more refined and safer treatments are made, including the better utilization of the antidepressant, and the anti-inflammatory and antioxidant effects of melatonin.

Keywords: IDO; SSRI; TDO; kynurenine; melatonin.

Figures

Figure 1
Figure 1
The predisposing, pregnancy and CUMS factors that contribute to PPD, both directly and via “baby blues” induce TDO and IDO, increasing TRYCATs, including KYNA and QUIN, as well as increasing PiCs and O&NS. Notes: Such increased immuno-inflammation drives down serotonin, melatonin, and á7nAChr, whilst increasing autoimmunity, somatization, and relative amygdalae–cortex activity. Along with decreased omega-3 polyunsaturated fatty acids, this increases PPD. Treatments include psychotherapy and antidepressants. Estrogen can enhance the efficacy of SSRIs, whilst melatonin may provide a safer treatment for both mother and child. Some antidepressants are not recommended if breastfeeding, including those where no relevant data exist. Abbreviations: á7nAChr, alpha 7 nicotinic acetylcholine receptor; CUMS, chronic unpredictable mild stress; E2, estradiol; EDO, indoleamine 2,3-dioxygenase; kyn, kynurenine; KYNA, kynurenic acid; MDD, major depressive disorder; O&NS, oxidative and nitrosative stress; PIC, proinflammatory cytokine; PPD, postpartum depression; QUIN, quinolinic acid; SES, socioeconomic status; SSI, selective serotonin reuptake inhibitor; T3, thyroid hormone; TDO, tryptophan 2,3-dioxygenase; TRYCAT, tryptophan catabolite.

References

    1. Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ) 2005;119:1–8.
    1. Harris B. Biological and hormonal aspects of postpartum depressed moods. Br J Psychiatry. 1994;164(3):288–292.
    1. Llewellyn AM, Stowe ZN, Nemeroff CB. Depression during pregnancy and the puerperium. J Clin Psychiatry. 1997;58(Suppl 15):26–32.
    1. Hirst KP, Moutier CY. Postpartum major depression. Am Fam Physician. 2010;82(8):926–933.
    1. Martin-Santos R, Gelabert E, Subira A, et al. Is neuroticism a risk factor for postpartum depression? Psychol Med. 2012;42:1559–1565.
    1. Hoedjes M, Berks D, Vogel I, et al. Postpartum depression after mild and severe preeclampsia. J Womens Health (Larchmt) 2011;20(10):1535–1542.
    1. Field T. Postpartum depression effects on early interactions, parenting, and safety practices: a review. Infant Behav Dev. 2010;33(1):1–6.
    1. Goodman SH, Gotlib IH. Risk for psychopathology in the children of depressed mothers: a developmental model for understanding mechanisms of transmission. Psychol Rev. 1999;106(3):458–490.
    1. Walker MJ, Davis C, Al-Sahab B, Tamim H. Reported maternal post-partum depression and risk of childhood psychopathology. Matern Child Health J
    1. Pawlby S, Hay DF, Sharp D, Waters CS, O’Keane V. Antenatal depression predicts depression in adolescent offspring: prospective longitudinal community-based study. J Affect Dis. 2009;113:236–243.
    1. De Vriese SR, Christophe AB, Maes M. Fatty acid composition of phospholipids and cholesteryl esters in maternal serum in the early puerperium. Prostaglandins Leukot Essent Fatty Acids. 2003a;68(5):331–335.
    1. De Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyun-saturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 2003;73(25):3181–3187.
    1. Shapiro GD, Fraser WD, Séguin JR. Emerging risk factors for post-partum depression: serotonin transporter genotype and omega-3 fatty acid status. Can J Psychiatry. 2012;57(11):704–712.
    1. Christesen HT, Falkenberg T, Lamont RF, Jørgensen JS. The impact of vitamin D on pregnancy: a systematic review. Acta Obstet Gynecol Scand. 2012;91(12):1357–1367.
    1. Milgrom J, Skouteris H, Worotniuk T, Henwood A, Bruce L. The association between ante- and postnatal depressive symptoms and obesity in both mother and child: a systematic review of the literature. Womens Health Issues. 2012;22(3):e319–e328.
    1. Skalkidou A, Sylvén SM, Papadopoulos FC, Olovsson M, Larsson A, Sundstrom-Poromaa I. Risk of postpartum depression in association with serum leptin and interleukin-6 levels at delivery: A nested case – control study within the UPPSAT cohort. Psychoneuroendocrinology. 2009;34:1329–1337.
    1. Bloch M, Meiboom H, Lorberblatt M, Bluvstein I, Aharonov I, Schreiber S. The effect of sertraline add-on to brief dynamic psychotherapy for the treatment of postpartum depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(2):235–241.
    1. Paskova A, Jirak R, Mikesova M, et al. The role of steroids in the development of post-partum mental disorders. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. Nov 12, 2012.
    1. Miller LJ. Postpartum depression. JAMA. 2002;287(6):762–765.
    1. Nappi RE, Petraglia F, Luisi S, Polatti F, Farina C, Genazzani AR. Serum allopregnanolone in women with postpartum “blues”. Obstet Gynecol. 2001;97(1):77–80.
    1. D Rheim SK, Bjorvatn BR, Eberhard-Gran M. Insomnia and depressive symptoms in late pregnancy: a population-based study. Behav Sleep Med. 2012;10(3):152–166.
    1. Silva R, Jansen K, Souza L, et al. Sociodemographic risk factors of perinatal depression: a cohort study in the public health care system. Rev Bras Psiquiatr. 2012;34(2):143–148.
    1. Lancaster CA, Gold KJ, Flynn HA, Yoo H, Marcus SM, Davis MM. Risk factors for depressive symptoms during pregnancy: a systematic review. Am J Obstet Gynecol. 2010;202(1):5–14.
    1. Skrundz M, Bolten M, Nast I, Hellhammer DH, Meinlschmidt G. Plasma oyxtocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology. 2011;36:1886–1893.
    1. Feldman R, Weller A, Zagoory-Sharon O, Levine A. Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding. Psychol Sci. 2007;18:965–970.
    1. Gordon I, Zagoory-Sharon O, Leckman JF, Feldman R. Oxytocin and the development of parenting in humans. Biol Psychiatry. 2010;68:377–382.
    1. Ozsoy S, Esel E, Kula M. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res. 2009;169:249–252.
    1. Fasching PA, Faschingbauer F, Goecke TW, et al. Genetic variants in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. J Psychiatr Res. 2012;46(9):1109–1117.
    1. Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpé S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci. 2002;71(16):1837–1848.
    1. Boufidou F, Lambrinoudaki I, Argeitis J, et al. CSF and plasma cytokines at delivery and postpartum mood disturbances. J Affect Disord. 2009;115(1–2):287–292.
    1. Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses. 2011;76:54–60.
    1. Pocivavsek A, Wu HQ, Elmer GI, Bruno J P, Schwarcz R. Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci. 2012;35(10):1605–1612.
    1. Ohira K, Hagihara H, Toyama K, et al. Expression of tryptophan 2,3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Mol Brain. 2010;3:26.
    1. Funakoshi H, Kanai M, Nakamura T. Modulation of tryptophan metabolism, promotion of neurogenesis and alteration of anxiety-related behavior in tryptophan 2,3-dioxygenase-deficient mice. Int J Tryptophan Res. 2011;4:7–18.
    1. Ren S, Correia MA. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase. Arch Biochem Biophys. 2000;377(1):195–203.
    1. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res. 2010;210(1):84–91.
    1. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: focus on individual differences. Pharmacol Biochem Behav. 2011;98:161–168.
    1. Haller J, Mikics E, Halász J, Tóth M. Mechanisms differentiating normal from abnormal aggression: glucocorticoids and serotonin. Eur J Pharmacol. 2005 Dec 5;526(1–3):89–100.
    1. Fuxe K, Jacobsen KX, Höistad M, et al. The dopamine D1 receptor-rich main and paracapsular intercalated nerve cell groups of the rat amygdala: relationship to the dopamine innervation. Neuroscience. 2003;119(3):733–746.
    1. Love TM, Enoch MA, Hodgkinson CA, et al. Oxytocin gene polymorphisms influence human dopaminergic function in a sex-dependent manner. Biol Psychiatry. 2012;72(3):198–206.
    1. Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation. 2011;8:94.
    1. Girdler SS, Klatzkin R. Neurosteroids in the context of stress: implications for depressive disorders. Pharmacol Ther. 2007;116(1):125–139.
    1. Brunton PJ, Bales J, Russell JA. Allopregnanolone and induction of endogenous opioid inhibition of oxytocin responses to immune stress in pregnant rats. J Neuroendocrinol. 2012;24(4):690–700.
    1. Anderson G, Maes M, Berk M. inflammation-related disorders in the tryptophan catabolite (TRYCAT) pathway in depression and somatization. Adv Protein Chem Struct Biol. 2012;88:27–48.
    1. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatr Res. 2012;196(23):243–249.
    1. Anderson G, Maes M, Berk M. Biological underpinnings of the commonalities in depression, somatization, and chronic fatigue syndrome. Med Hypotheses. 2012;78:752–756.
    1. Lou HY, Kong JF. The effects of prenatal maternal depressive symptoms on pain scores in the early postpartum period. J Obstet Gynaecol. 2012;32(8):764–766.
    1. Groer M W, Morgan K. Immune, health and endocrine characteristics of depressed postpartum mothers. Psychoneuroendocrinology. 2007;32(2):133–139.
    1. Meinlschmidt G, Martin C, Neumann ID, Heinrichs M. Maternal cortisol in late pregnancy and hypothalamic-pituitary-adrenal reactivity to psychosocial stress postpartum in women. Stress. 2010;13(2):163–171.
    1. Yim IS, Glynn LM, Dunkel-Schetter C, Hobel CJ, Chicz-DeMet A, Sandman CA. Risk of postpartum depressive symptoms with elevated corticotropin-releasing hormone in human pregnancy. Arch Gen Psychiatry. 2009;66(2):162–169.
    1. Xie P, Kranzler HR, Poling J, et al. Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder. Neuropsychopharmacology. 2010;35(8):1684–1692.
    1. Salel ES, El-Bahei W, El-Hadidy MA, Zayed A. Predictors of postpartum depression in a sample of Egyptian women. Neuropsychiatric Dis Treat. 2013;9:15–24.
    1. Newcomer JW, Selke G, Melson AK, Gross J, Vogler G P, Dagogo-Jack S. Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans. Arch Gen Psychiatry. 1998;55:995–1000.
    1. Luchowska E, Kloc R, Olajossy B, et al. Beta2 adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signalling. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):519–529.
    1. De Rosa V, Procaccini C, Calì G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007;26:241–255.
    1. Fukuda M, Williams K W, Gautron L, Elmquist JK. Induction of leptin resistance by activation of cAMP-Epac signaling. Cell Metab. 2011;13:331–339.
    1. Gupta BB, Yanthan L, Singh KM. In vitro effects of 5-hydroxytryptophan, indoleamines and leptin on arylalkylamine N-acetyltransferase (AA-NAT) activity in pineal organ of the fish, Clarias gariepinus (Burchell, 1822) during different phases of the breeding cycle. Indian J Exp Biol. 2010;48(8):786–792.
    1. Maes M, Lin AH, Ombelet W, et al. Immune activation in the early puerperium is related to postpartum anxiety and depressive symptoms. Psychoneuroendocrinology. 2000;25(2):121–137.
    1. Maes M, Ombelet W, Libbrecht II, et al. Effects of pregnancy and delivery on serum concentrations of Clara Cell Protein (CC16), an endogenous anticytokine: lower serum CC16 is related to postpartum depression. Psychiatry Res. 1999;87(2–3):117–127.
    1. Maes M, Ombelet W, De Jongh R, Kenis G, Bosmans E. The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. J Affect Disord. 2001;63(1–3):85–92.
    1. Maes M, Bosmans E, Ombelet W. In the puerperium, primiparae exhibit higher levels of anxiety and serum peptidase activity and greater immune responses than multiparae. J Clin Psychiatry. 2004;65(1):71–76.
    1. Maes M, Claes M, Schotte C, et al. Disturbances in dexamethasone suppression test and lower availability of L-tryptophan and tyrosine in early puerperium and in women under contraceptive therapy. J Psychosom Res. 1992;36(2):191–197.
    1. Maes M, Ombelet W, Verkerk R, Bosmans E, Scharpé S. Effects of pregnancy and delivery on the availability of plasma tryptophan to the brain: relationships to delivery-induced immune activation and early post-partum anxiety and depression. Psychol Med. 2001;31(5):847–858.
    1. Maes M, Ringel K, Kubera M, Berk M, Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord. 2012;136(3):386–392.
    1. Donne ML, Settineri S, Benvenga S. Early pospartum alexithymia and risk for depression: relationship with serum thyrotropin, free thyroid hormones and thyroid autoantibodies. Psychoneuroendocrinology. 2012;37(4):519–533.
    1. Sylvén SM, Elenis E, Michelakos T, et al. Thyroid function tests at delivery and risk for postpartum depressive symptoms. Psychoneuroendocrinology. :2013.
    1. Maes M, Ringel K, Kubera M, et al. In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation In press . :2013.
    1. Groër M, Davis M, Casey K, Short B, Smith K, Groër S. Neuroendocrine and immune relationships in postpartum fatigue. MCN Am J Matern Child Nurs. 2005;30(2):133–138.
    1. Morris G, Maes M. A neuro-immune model of myalgic encephalomyelitis/chronic fatigue syndrome. Metab Brain Dis. :2013.
    1. Di Scalea TL, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol. 2009;52(3):483–497.
    1. Nascimento SL, Surita FG, Cecatti JG. Physical exercise during pregnancy: a systematic review. Curr Opin Obstet Gynecol. 2012;24(6):387–394.
    1. Sado M, Ota E, Stickley A, Mori R. Hypnosis during pregnancy, childbirth, and the postnatal period for preventing postnatal depression. Cochrane Database Syst Rev. 2012;6:CD009062.
    1. Hübner-Liebermann B, Hausner H, Wittmann M. Recognizing and treating peripartum depression. Dtsch Arztebl Int. 2012;109(24):419–424.
    1. Ng RC, Hirata CK, Yeung W, Haller E, Finley PR. Pharmacologic treatment for postpartum depression: a systematic review. Pharmacotherapy. 2010;30(9):928–941.
    1. Yonkers KA, Lin H, Howell HB, Heath AC, Cohen LS. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. J Clin Psychiatry. 2008;69(4):659–665.
    1. Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ. 1997;314(7085):932–936.
    1. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53.
    1. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry. 1998;44(9):839–850.
    1. Pae CU, Mandelli L, Kim TS, et al. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomed Pharmacother. 2009;63(3):228–235.
    1. Fortinguerra F, Clavenna A, Bonati M. Psychotropic drug use during breast feeding: a review of the evidence. Pediatrics. 2009;124(4):e547–e556.
    1. Weissman A, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(16):1066–1078.
    1. Payne JL. Antidepressant use in the postpartum period: practical consideration. Am J Psychiatry. 2007;164(9):1329–1332.
    1. Berle JO, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011;7:28–34.
    1. Davanzo R, Copertino M, De Cunto A, Minen F, Amaddeo A. Antidepressant drugs and breastfeeding: a review of the literature. Breastfeed Med. 2011;6(2):89–98.
    1. Cutler JA, Rush AJ, McMahon FJ, Laje G. Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J Psychopharmacol. 2012;26(3):360–367.
    1. Maneeton N, Thongkam A, Maneeton B. Cognitive-behavioral therapy added to fluoxetine in major depressive disorder after 4 weeks of fluoxetine-treatment: 16-week open label study. J Med Assoc Thai. 2010;93(3):337–342.
    1. Sarkar S, Gupta R. Telephone vs face-to-face cognitive behavioural therapy for depression. JAMA. 2012;308(11):1090–1091.
    1. Bloch M, Schmidt PJ, Danaceau M, et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157(6):924–930.
    1. Wjeik J, Dudek D, Schlegel-Zawadzka M, et al. Antepartum/postpartum depressive symptoms and serum zinc and magnesium levels. Pharmacol Rep. 2006;58:571–576.
    1. Eby GA, Eby KL. Rapid recovery from major depression using magnesium treatment. Med Hypotheses. 2006;67:362–370.
    1. Nakagawasai O, Murata A, Arai Y, et al. Enhanced head-twitch response to 5-HT-related agonists in thiamine. J Neural Transm. 2007;114:1003–1010.
    1. Nikseresht S, Etebary S, Karimian M, Nabavizadeh F, Zarrindast MR, Sadeghipour HR. Acute administration of Zn, Mg, and thiamine improves postpartum depression conditions in mice. Arch Iran Med. 2012;15(5):306–311.
    1. Studd J W. A guide to the treatment of depression in women by estrogens. Climacteric. 2011;14(6):637–642.
    1. Ryan J, Scali J, Carrière I, et al. Estrogen receptor alpha gene variants and major depressive episodes. J Affect Disord. 2012;136(3):1222–1226.
    1. Anderson G. The role of melatonin in postpartum psychosis and depression associated with bipolar disorder. J Perinat Med. 2010;38(6):585–587.
    1. Etain B, Dumaine A, Bellivier F, et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet. 2012;21(18):4030–4037.
    1. Galecka E, Szemraj J, Florkowski A, et al. Single nucleotide polymorphisms and mRNA expression for melatonin MT(2) receptor in depression. Psychiatry Res. 2011;189(3):472–474.
    1. Parry BL, Meliska CJ, Sorenson DL, et al. Plasma melatonin circadian rhythm disturbances during pregnancy and postpartum in depressed women and women with personal or family histories of depression. Am J Psychiatry. 2008;165(12):1551–1558.
    1. Hardeland R, Cardinali D P, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin – a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93:350–384.
    1. Lanoix D, Beghdadi H, Lafond J, Vaillancourt C. Human placental trophoblasts synthesize melatonin and express its receptors. J Pineal Res. 2008;45(1):50–60.
    1. Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J Pineal Res. 2009;46:128–139.
    1. Cohen Engler A, Hadash A, Shehadeh N, Pillar G. Breastfeeding may improve nocturnal sleep and reduce infantile colic: potential role of breast milk melatonin. Eur J Pediatr. 2012;171(4):729–732.
    1. Pontes GN, Cardoso EC, Carneiro-Sampaio MM, Markus RP. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppress nocturnal melatonin production. J Pineal Res. 2007;43:365–371.
    1. Wloch C, Wilson J, Lamagni T, Harrington P, Charlett A, Sheridan E. Risk factors for surgical site infection following caesarean section in England: results from a multicentre cohort study. BJOG. 2012;119(11):1324–3133.
    1. Eisenach JC, Pan PH, Smiley R, Lavand’homme P, Landau R, Houle TT. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain. 2008;140(1):87–94.
    1. Andreasen JT, Redrobe JP, Nielsen EØ. Combined á7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. Pharmacol Biochem Behav. 2012;100(3):624–629.
    1. Fernandez J W, Grizzell JA, Wecker L. The role of estrogen receptor â and nicotinic cholinergic receptors in postpartum depression. Prog Neuropsychopharmacol Biol Psychiatry. 2012;40C:199–206.
    1. Cosi C, Mannaioni G, Cozzi A, et al. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacolog y. 2011;60:1227–1231.
    1. Markus R P, Silva CLM, Franco DG, Barbosa EM, Jr, Ferreira ZS. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? Pharmacol Therapeut. 2010;126:251–262.
    1. Bennet S, Alpert M, Kubulins V, Hansler RL. Use of modified spectacles and light bulbs to block blue light at night may prevent postpartum depression. Med Hypotheses. 2009;73(2):251–253.
    1. Sharkey JT, Cable C, Olcese J. Melatonin sensitizes human myometrial cells to oxytocin in a protein kinase C alpha/extracellular-signal regulated kinase-dependent manner. J Clin Endocrinol Metab. 2010;95(6):2902–2908.
    1. Juszczak M, Boczek-Leszczyk E. Hypothalamic gonadotropin-releasing hormone receptor activation stimulates oxytocin release from the rat hypothalamo-neurohypophysial system while melatonin inhibits this process. Brain Res Bull. 2010;81(1):185–190.
    1. Labuschagne I, Phan KL, Wood A, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology. 2010;35:2403–2413.
    1. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry. 2003;54:1389–1398.
    1. Srinivasan V, Zakaria R, Othman Z, Lauterbach EC, Acuña-Castroviejo D. Agomelatine in depressive disorders: its novel mechanisms of action. J Neuropsychiatry Clin Neurosci. 2012;24(3):290–308.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa